PURE Bioscience, Inc. ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.
Summary of Results ? Fiscal.
QUANTUM COMPUTING INC. Unaudited condensed consolidated financial information of the Company as of March 31, 2024 and for the three months ended March 31, 2024 and 2023. .
06.06.2024 - Exceeded Revenue and Adjusted EBITDA Guidance for Q1 2024. Improved Business Momentum in Q1 2024. Record Low Quarterly Cash Consumption in Q1 2024. Reiterates Expectation for Revenue Growth and Free Cash Flow Breakeven in FY 2024. NEW YORK, .